|
1
|
Lei P, Xie J, Wang L, Yang X, Dai Z and Hu
Y: microRNA-145 inhibits osteosarcoma cell proliferation and
invasion by targeting ROCK1. Mol Med Rep. 10:155–160.
2014.PubMed/NCBI
|
|
2
|
Jaffe N: Osteosarcoma: Review of the past,
impact on the future. The American experience. Cancer Treat Res.
152:239–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferguson WS and Goorin AM: Current
treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hameed M and Dorfman H: Primary malignant
bone tumours - recent developments. Semin Diagn Pathol. 28:86–101.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li R, Liu J, Wu H, Liu L, Wang L and Zhang
S: TIKI2 suppresses growth of osteosarcoma by targeting
Wnt/β-catenin pathway. Mol Cell Biochem. 392:109–116. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mao JH, Zhou RP, Peng AF, Liu ZL, Huang
SH, Long XH and Shu Y: microRNA-195 suppresses osteosarcoma cell
invasion and migration in vitro by targeting FASN. Oncol Lett.
4:1125–1129. 2012.PubMed/NCBI
|
|
7
|
Jiang Y, Liu YE, Goldberg ID and Shi YE:
Gamma synuclein, a novel heat-shock protein-associated chaperone,
stimulates ligand-dependent estrogen receptor alpha signaling and
mammary tumorigenesis. Cancer Res. 64:4539–4546. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao
G, Joseph BK, Rosen C and Shi YE: Identification of a breast
cancer-specific gene, BCSG1, by direct differential cDNA
sequencing. Cancer Res. 57:759–764. 1997.PubMed/NCBI
|
|
9
|
Morgan J, Hoekstra AV, Chapman-Davis E,
Hardt JL, Kim JJ and Buttin BM: Synuclein-γ (SNCG) may be a novel
prognostic biomarker in uterine papillary serous carcinoma. Gynecol
Oncol. 114:293–298. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hibi T, Mori T, Fukuma M, Yamazaki K,
Hashiguchi A, Yamada T, Tanabe M, Aiura K, Kawakami T, Ogiwara A,
et al: Synuclein-γ is closely involved in perineural invasion and
distant metastasis in mouse models and is a novel prognostic factor
in pancreatic cancer. Clin Cancer Res. 15:2864–2871. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Han S, She F, Wang D, Yao X, Jiang L and
Chen Y: SNCG gene silencing in gallbladder cancer cells inhibits
key tumorigenic activities. Front Biosci (Landmark Ed).
17:1589–1598. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pan ZZ, Bruening W, Giasson BI, Lee VM and
Godwin AK: Gamma-synuclein promotes cancer cell survival and
inhibits stress- and chemotherapy drug-induced apoptosis by
modulating MAPK pathways. J Biol Chem. 277:35050–35060. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C,
Wang L, Zhao W, Jiang JD and Liu J: Loss of epigenetic control of
synuclein-γ gene as a molecular indicator of metastasis in a wide
range of human cancers. Cancer Res. 65:7635–7643. 2005.PubMed/NCBI
|
|
14
|
Dorfman HD, Czemiak B and Kotz R: World
Health Organization Classification of TumoursWorld Health
Organization Classification of Tumours, Pathology and Genetics of
Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK and Mertens
F: IARC Press; Lyon, France: pp. 227–232. 2002
|
|
15
|
Enneking WF: Staging musculoskeletal
tumorsMusculoskeletal Tumor Surgery. Churchill Livingstone; New
York: pp. 69–122. 1983
|
|
16
|
Li P, Xie XB, Chen Q, Pang GL, Luo W, Tu
JC, Zheng F, Liu SM, Han L, Zhang JK, et al: MiRNA-15a mediates
cell cycle arrest and potentiates apoptosis in breast cancer cells
by targeting synuclein-gamma. Asian Pac J Cancer Prev.
15:6949–6954. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou X, Jing J, Peng J, Mao W, Zheng Y,
Wang D, Wang X, Liu Z and Zhang X: Expression and clinical
significance of galectin-3 in osteosarcoma. Gene. 546:403–407.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shweikeh F, Bukavina L, Saeed K, Sarkis R,
Suneja A, Sweiss F and Drazin D: Brain metastasis in bone and soft
tissue cancers: A review of incidence, interventions, and outcomes.
Sarcoma. 2014:4751752014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Link MP, Gebhardt MC and Meyers PA:
Chapter 35: OsteosarcomaPrinciples and Practice of Pediatric
Oncology. Pizzo PA and Poplack DG: 5th. Lippincott Williams &
Wilkins; Philadelphia, PA: pp. 1051–1089. 2006
|
|
21
|
Taheriazam A, Bahador R, Karbasy SH,
Jamshidl SM, Torkaman A, Yahaghi E and Shakeri M: Down-regulation
of microRNA-26a and up-regulation of microRNA-27a contributes to
aggressive progression of osteosarcoma. Diagn Pathol. 10:1662015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang T, Ji F, Dai Z, Xie Y and Yuan D:
Increased expression of microRNA-191 as a potential serum biomarker
for diagnosis and prognosis in human osteosarcoma. Cancer Biomark.
15:543–550. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ninkina NN and Bukhman VL: Synucleins - to
have or not to have. Genetika. 36:1487–1491. 2000.(In Russian).
PubMed/NCBI
|
|
24
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang W, Ren F, Wu Q, Jiang D, Li H and Shi
H: MicroRNA-497 suppresses angiogenesis by targeting vascular
endothelial growth factor A through the PI3K/AKT and MAPK/ERK
pathways in ovarian cancer. Oncol Rep. 32:2127–2133.
2014.PubMed/NCBI
|
|
26
|
Han J, Huo M, Mu M, Liu J and Zhang J:
miR-497 suppresses proliferation of human cervical carcinoma HeLa
cells by targeting cyclin E1. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
30:597–600. 2014.(In Chinese). PubMed/NCBI
|
|
27
|
Li W, Jin X, Deng X, Zhang G, Zhang B and
Ma L: The putative tumor suppressor microRNA-497 modulates gastric
cancer cell proliferation and invasion by repressing eIF4E. Biochem
Biophys Res Commun. 449:235–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xie Y, Wei RR, Huang GL, Zhang MY, Yuan YF
and Wang HY: Checkpoint kinase 1 is negatively regulated by miR-497
in hepatocellular carcinoma. Medical Oncology. 31:8442014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ohba T, Cates JM, Cole HA, Slosky DA, Haro
H, Ando T, Schwartz HS and Schoenecker JG: Autocrine VEGF/VEGFR1
Signaling in a Subpopulation of Cells Associates with Aggressive
Osteosarcoma. Molecular Cancer Research molcanres. 0037.2014. 2014.
View Article : Google Scholar
|
|
30
|
Liu H, Huang L, Zhang Z, Zhang Z, Yu Z,
Chen X, Chen Z, Zen Y, Yang D, Han Z, et al: LIM mineralization
protein-1 inhibits the malignant phenotypes of human osteosarcoma
cells. International journal of molecular sciences. 15:7037–7048.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He H, Ni J and Huang J: Molecular
mechanisms of chemoresistance in osteosarcoma. Oncol Lett.
7:1352–1362. 2014.(Review). PubMed/NCBI
|
|
32
|
Zhang H, Yin Z, Ning K, Wang L, Guo R and
Ji Z: Prognostic value of microRNA-223/epithelial cell transforming
sequence 2 signaling in patients with osteosarcoma. Hum Pathol.
45:1430–1436. 2014. View Article : Google Scholar : PubMed/NCBI
|
